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ABSTRACT

Stimuli-responsive nanocarriers have attracted increasing attention for drug and gene delivery in
cancer therapy. The present study reports the development of redox-sensitive dendrimersomes
made of disulphide-linked cholesterol-bearing PEGylated dendrimers, that can be used as drug
and gene delivery systems. Two disulphide-linked cholesterol-bearing PEGylated generation 3diaminobutyric polypropylenimine dendrimers have been successfully synthesized through in
situ two-step reaction. They were able to spontaneously self-assemble into stable, cationic,
nanosized vesicles (or dendrimersomes), with lower critical aggregation concentration values for
high cholesterol-bearing vesicles. These dendrimersomes were able to entrap both hydrophilic
and hydrophobic dyes, and also showed a redox-responsive sustained release of the entrapped
guests in presence of a glutathione concentration similar to that of the cytosolic reducing
environment. The high cholesterol-bearing dendrimersome was found to have a higher melting
enthalpy, an increased adsorption tendency on mica surface, was able to entrap a larger amount
of hydrophobic drug and was more resistant to redox-responsive environment in comparison
with its low cholesterol counterpart. In addition, both dendrimersomes were able to condense
more than 85% of the DNA at all tested ratios for the low-cholesterol vesicles, and at dendrimer:
DNA weight ratios of 1:1 and higher for the high-cholesterol vesicles. These vesicles resulted in
an enhanced cellular uptake of DNA, by up to 15-fold compared with naked DNA with the lowcholesterol vesicles. As a result, they increased gene transfection on PC-3 prostate cancer cell
line, with the highest transfection being obtained with low-cholesterol vesicle complex at a
dendrimer: DNA weight ratio of 5:1 and high-cholesterol vesicle complex at a dendrimer: DNA
weight ratio of 10:1. These transfection levels were about 5-fold higher than that observed when
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treated with DNA. These cholesterol-bearing PEGylated dendrimer-based vesicles are therefore
promising as redox-sensitive drug and gene delivery systems for potential applications in
combination cancer therapy.
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INTRODUCTION
Despite recent advances in the field of cancer gene therapy, the possibility of using therapeutic
genes combined with anti-cancer drugs for cancer treatment is still hampered by the lack of safe
delivery systems able to carry both therapeutic DNA and drug simultaneously and to selectively
deliver them to the tumors, without secondary effects to healthy tissues. 1 The synthesis of novel
“smart” delivery systems able to overcome these issues is therefore urgently needed. In order to
remediate this issue, we propose to conjugate cholesterol and PEG to the surface of generation 3diaminobutyric polypropylenimine (DAB) dendrimer, with a redox-sensitive disulphide linkage,
and evaluate the potential use of this novel dendrimer as a drug and gene delivery system.
Cationic dendrimers are emerging as potential non-viral vectors for delivering nucleic acids
and anti-cancer drugs to cancer cells. These polymers are highly branched, three-dimensional
macromolecules with modifiable surface functionalities that have been largely exploited to
achieve the conjugation of targeting moieties and the binding of drugs or nucleic acids for
therapeutic applications. Furthermore, their constitutive dendrons delimitate internal cavities,
that can be used for the encapsulation of various chemically sensitive drugs. Their high aqueous
solubility, low toxicity, compact globular shape made them ideal carriers for anti-cancer drugs. 2
Dendrimers can also facilitate the passive targeting of anti-cancer drugs to tumor tissue. This
selective accumulation of macromolecules in tumors, termed “enhanced permeability and
retention (EPR) effect”, is the consequence of the combination of reduced lymphatic drainage
and increased permeability of tumor vasculature to macromolecules.
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Positively charged

dendrimers can form stable ionic complexes with negatively charged plasmid DNA, but also
bind easily to the negatively charged cell surface through electrostatic interactions, leading to
their cellular internalization by endocytosis. 4-6
4

In this work, we have chosen to use generation 3-diaminobutyric polypropylenimine (DAB)
dendrimer, as it has been reported to be more efficacious than its higher generations for gene
transfection.
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In addition, we recently demonstrated that tumor-targeted generation 3-DAB

dendrimer complexed to therapeutic plasmid DNA led to successful gene expression and
therapeutic efficacy in mice bearing subcutaneous tumors following intravenous injection. 8-12
Recently, the development of various self-assembled nanostructures (such as micelles, vesicles
or dendrimersomes) based on surface-modified amphiphilic dendrimers following conjugation
with diverse hydrophobic groups (such as aromatic, long hydrophobic chains, fluorinated
groups) has shown promises for further biomedical applications.

13-15

Since the hydrophobic

interactions are one of the main driving forces for any aggregated structure, the conjugation of
lipidic alkyl chains to dendrimers would not only increase the hydrophobicity of the dendrimers
and facilitate their self-assembly, but would also make them form more compact and smaller
sized dendriplexes. 16-17 Based on this, we have chosen to conjugate DAB dendrimer with a more
lipophilic moiety, cholesterol, which is an essential structural and functional constituent of
animal cell membrane. Due to its higher hydrophobicity compared with the hydrocarbon chains
of fatty acids, cholesterol has been previously used for the synthesis of polymer- and surfactantbased self-assembled nanostructures.

18-20

Cholesterol enhances the stability of the hydrophobic

rigid microenvironment of nanostructures, helps drug delivery systems to cross the cellular
membrane more easily, and also increases the transfection efficacy of cholesterol-based gene
vectors in various cell lines due to its strong fusogenic activity. 21
Poly(ethylene glycol) (PEG) will also be conjugated to the cholesterol-bearing DABdendrimer as this stealth material was previously reported to increase the water solubility and to
reduce non-specific interactions with circulatory proteins, thus leading to an enhanced
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circulatory life time of drug and gene delivery systems.

22-25

We recently demonstrated that the

conjugation of low molecular weight PEG (2 kDa) to generation 3- and generation 4-DAB
dendrimers significantly decreased their cytotoxicity on B16F10-Luc cells, by more than 3.4-fold
compared to unmodified dendrimers.

26

In addition, these PEGylated dendrimers complexed to

DNA at dendrimer: DNA ratios of 20:1 and 10:1 were able to increase gene expression on
B16F10-Luc, A431, DU145, PC3-Luc cells lines, compared to the unmodified dendriplex.
Stimuli- responsive polymers have gained widespread interest as they are able to undergo
structural changes in the presence of an external stimulus such as pH, light or redox. In this
regard, amphiphilic dendrimers containing a disulphide linkage in their structural backbone are
particularly interesting, as this group can be cleaved into the corresponding thiols in presence of
a reducing biothiol, such as glutathione (GSH), triggering the destruction of the delivery systems
and the release of the guest at the desired site of action. 27 This is particularly important in cancer
therapy, as glutathione is present in abundance in cancer cells: its concentration was found to be
different in intracellular (~10 mM) and extracellular (<10 µM) compartments of living cells. It is
nearly 4-fold higher than that of normal tissue in cancer cells. 27
The objectives of this study were therefore 1) to synthesize and characterize disulphide-linked
cholesterol-bearing PEGylated amphiphilic DAB dendrimers, 2) to evaluate their self-assembly
formation into nanostructures and their ability to entrap drugs, 3) to assess the redox sensitivity
of these nanostructures, 4) to evaluate DNA condensation by the dendrimer-based nanostructures
and 5) to assess the cell viability, cellular uptake and transfection efficacy of these structures
complexed with DNA on prostate cancer cells in vitro.
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MATERIALS AND METHODS
Materials
Generation 3- diaminobutyric polypropylenimine dendrimer (DAB) was purchased from SyMOChem (Eindhoven, The Netherlands). Thiocholesterol (CHOLSH), glutathione (GSH),
trimethylamine (TEA), N-Phenyl-1-naphthylamine (NPN), Nile Red, Rhodamine 6G (R6G),
trifluoroacetic acid (TFA), the deuterated solvents CDCl3 and D2O, and a double-sided
Biodialyser (sample reservoir size: 1 mL) were obtained from Sigma Aldrich (Poole, UK).
Anhydrous tetrahydrofuran (THF), acetonitrile (HPLC grade) and methanol (MeOH) came from
Fisher Scientific (Loughborough, UK). Orthopyridyl disulfide (OPSS) polyethylene glycol
(PEG) succinimidyl carboxymethyl ester (OPSS-PEG-SCM) was purchased from JenKem
Technology (Plano, TX). The expression plasmid encoding β-galactosidase (pCMVsport βgalactosidase) was obtained from Invitrogen (Paisley, UK). It was purified using an Endotoxinfree Giga Plasmid Kit (Qiagen, Hilden, Germany). Quanti-iT® PicoGreen® dsDNA reagent and
tissue culture media were purchased from Life Technologies (Paisley, UK). Vectashield®
mounting medium containing 4’,6-diamidino-2-phenylindole (DAPI) came from Vector
Laboratories (Peterborough, UK). Label IT® Fluorescein Nucleic Acid Labeling Kit was
obtained from Cambridge Biosciences (Cambridge, UK). Passive lysis buffer was obtained from
Promega (Southampton, UK). Bioware® androgen-irresponsive PC-3M-luc-C6 human prostate
adenocarcinoma that expresses the firefly luciferase was purchased from Caliper Life Sciences
(Hopkinton, MA).
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Synthesis and characterization of the disulphide-linked cholesterol-bearing PEGylated
dendrimers
Amine-terminated, generation 3-diaminobutyric poly(propyleneimine) dendrimer (DAB) was
first conjugated to PEG using OPSS PEG succinimidyl carboxymethyl ester (OPSS-PEG-SCM)
and then to thiocholesterol (CHOLSH) through disulphide linkage using MeOH-THF (5:1) as
solvent (Scheme 1). Briefly, TEA (20 equivalents, 66.2 µL) was added as a whole to a solution
of DAB (1 equivalent, 40 mg) in 1.5 mL MeOH. After 30 minutes of stirring at 20 oC, a freshly
prepared methanolic solution of OPSS-PEG-SCM (0.5 and 1 equivalents, 27.19 mg and 54.39
mg respectively for low- and high-cholesterol dendrimers, in 1.5 mL methanol) was added
dropwise to DAB over 10-12 minutes. The reaction mixture was then stirred at 37 oC for 6 h,
protected from light.
Thiocholesterol (0.5 and 1 equivalents (4.77 mg and 9.54 mg) respectively for low-cholesterol
and high-cholesterol dendrimers, in 0.6 mL THF) was then added as a whole to the reaction
mixture containing PEGylated DAB. The reaction mixture, initially colorless, gradually became
yellow, and was left stirring at 37 oC, protected from light. After 15 h, distilled water (5 mL) was
added to the reaction mixture. The water-soluble modified dendrimers were purified by dialysis
against distilled water (2 L), changed twice per day for 3 days at 25°C, using dialysis tubing with
a molecular weight cut-off of 3.5 kDa, to remove organic solvents and excess M-PEG, before
being filtrated with Whatman cellulose filter paper and freeze-dried using a Christ Epsilon 2-4
LSC freeze dryer (Osterode am Harz, Germany). The final product DAB-PEG-SS-CHOL
(DPSC), a white colored compound, was stored at 0-4 oC for long-term storage.
The infrared spectra of low- and high-cholesterol dendrimers, as well as all the starting materials,
were obtained using an IRSpirit® QATR-S Fourier Transform infrared (FTIR) spectrophotometer
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with attenuated total reflectance (ATR) probe (Shimadzu, Kyoto, Japan). Transmittance (4000–
400 cm–1) was recorded at a 4 cm–1 resolution, and spectra were processed with the LabSolutions
IR® software (Shimadzu, Kyoto, Japan). The 1H-NMR spectra of both low- and high-cholesterol
dendrimers (2-3 mg in 0.5 mL deuterated solvents) were recorded on a Bruker Avance ® IIIHD500 NMR spectrometer (Billerica, MA), using the residual proton resonance of the solvent as
the internal standard.

9

Scheme 1. General synthetic scheme of cholesterol-modified PEGylated dendrimers, with m=45.
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The molecular weights of low- and high-cholesterol dendrimers were determined by Matrixassisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry, using an
Axima-CFR® mass spectrometer (Kratos Analytical, Shimadzu, Kyoto, Japan) and α-Cyano-4hydroxycinnamic acid as the matrix. The matrix was prepared at a concentration of 10 mg/mL in
a solvent mixture (acetonitrile/water, 60/40 v/v, with 0.1% TFA). The sample solution (10 µL)
was added to the matrix solution (10 µL) in 1/1 (v/v) ratio and thoroughly mixed. One µL of this
mixture was then added to the MALDI sample plate and air-dried before measurement. The
instrument was operated in a linear mode with a 4 point calibration. A N2 laser operating at 337
nm was used to generate the ions before being accelerated to 20 kV.

Evaluation of the self-assembly formation of the dendrimers
The ability for low-and high-cholesterol dendrimers to self-assemble was assessed using a
steady-state fluorescence technique with N-Phenyl-1-naphthylamine (NPN) as fluorescence
probe molecule. To this end, 0.75 µL NPN stock solution (1.32 × 10−3 M, 2.89 mg in 10 mL
methanol) were added to 5-mL plastic vials. Following complete evaporation of the solvent after
5-6 h, 1 mL low- and high-cholesterol dendrimer solutions prepared at concentrations ranging
from 1 to 400 µg/mL in PBS (pH 7.4), was added to the vials, making the final probe
concentration 1 × 10−6 M. Each sample was vigorously vortexed for 5 minutes and then
incubated for 16 h at 20 oC, protected from light, before measurement. Fluorescence spectra of
NPN were then recorded with a Varian Cary Eclipse Fluorescence spectrophotometer (Palo Alto,
CA) (λexc: 340 nm, λem: 360-600 nm, excitation and emission slit at 5 nm and 10 nm
respectively).
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Hydrodynamic size and zeta potential of dendrimer self-assembled nanostructures
The hydrodynamic diameter (dH) and zeta potential of dendrimer self-assembled nanostructures
in aqueous medium (PBS, pH 7.4) at 37 oC were measured at concentrations ranging from 50 to
400 µg/mL (over CAC value) by dynamic light scattering (DLS) using a Malvern Nano ZS
instrument (Malvern Instruments, Malvern, UK). A 4 mW He-Ne laser (λ = 632.8 nm) was used
as a source and scattering photons were collected at 173o scattering angle.

Formation of low-and high-cholesterol dendrimer-based vesicles
Observation of the morphology of the self-assembled nanostructures
The morphology of the low-cholesterol and high-cholesterol dendrimer-based nanostructures
(400 µg/mL in PBS pH 7.4) was observed by transmission electron microscopy, using a JEOL
JEM-1200EX transmission electron microscope (Jeol, Tokyo, Japan) operating at an accelerating
voltage of 80 kV. Three µL of each sample in PBS (pH 7.4) was drop cast on a carbon-coated
copper grid (400 mesh size) and was kept in desiccators overnight for drying before imaging.

Encapsulation of hydrophilic dye R6G by the self-assembled nanostructures
R6G solution (1.02 x 10−2 M, 4.89 mg/mL in methanol, 28.18 µL and 19.85 µL) was respectively
added to 1.15 mg of low-cholesterol and 0.81 mg of high-cholesterol dendrimers. Following
evaporation of methanol by a stream of N2 gas, the mixture of dendrimers with R6G was soaked
in 1 mL PBS buffer pH 7.4 for 3 h (until the dispersion became homogeneous) and vortexed for
10 min. PBS buffer (pH 7.4) was then added to obtain a final dendrimer solution with a
concentration of 400 µg dendrimer per mL and 47 µg R6G per mL (1x10−4 M). The dendrimer
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solution containing R6G was vortexed for 2 min and incubated for 20 h at 25 oC to allow
encapsulation of the hydrophilic dye. To remove the unencapsulated dye, the dendrimer solution
(1 mL) was dialyzed in a double-sided Biodialyzer cell using a dialysis membrane with a
molecular weight cut-off of 2000 Da, against 60 mL PBS buffer (pH 7.4) for 24 h with 4 changes
of the buffer. The dialyzed solution was kept protected from light and its fluorescence was
quantified by spectrofluorimetry (λex: 480 nm, λem: 500-700 nm), using a Varian Cary Eclipse
spectrofluorometer (Agilent Technologies, Santa Clara, CA).

Thermal analysis of phase transition behavior of low-and high-cholesterol dendrimer-based
vesicles
Transmittance of low-cholesterol and high-cholesterol dendrimer-based vesicles (400 µg/mL in
PBS buffer pH 7.4) was measured at temperatures ranging from 20 oC to 90 oC, using a Varian
Model-Cary 5000 spectrophotometer (Agilent Technologies, Santa Clara, CA), with a Cary
automated temperature controller UV0904M400 (Agilent Technologies, Santa Clara, CA), to
measure the cloud point. Differential scanning calorimetry (DSC) measurements for lowcholesterol and high-cholesterol dendrimer-based vesicles (2 mg/mL in PBS pH 7.4) were done
using a Netzsch DSC214 Polyma differential scanning calorimeter (Netzsch-Gerätebau GmbH,
Selb, Germany) to measure the phase transition behavior of the vesicles. To this end, 3.1 ± 0.1
mg of sample was transferred to a 40 μL aluminium pan by micropipetting. Pans were
hermetically sealed with aluminium lids. Blank and reference pans were prepared with 3.1 ± 0.1
mg of PBS solution. Samples were cooled to -15°C at a rate of 2 °C/min and held for 5 min at 15°C prior to heating at a rate of 2 °C/min. A repeat cycle was carried out on each sample. Blank
correction was carried out with the PBS solution under the same measurement conditions prior to
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sample analysis. Analysis of the results was carried out with Netzsch Proteus Analysis Software
v7.0.1 (Netzsch-Gerätebau GmbH, Selb, Germany), with onset temperature, peak temperature
and enthalpy of measured peaks determined.

Atomic force microscopy (AFM) imaging of dendrimer-based vesicles
Low-cholesterol and high-cholesterol dendrimer-based vesicles were visualized by atomic force
microscopy (AFM) to assess their size and shape. Data were collected by a Dimension Icon®
AFM (Bruker, Santa Barbara, CA) using a PeakForce Tapping® scanning mode at 20 oC with a
ScanAsyst-Air® probe (Bruker, Santa Barbara, CA) with nominal spring constant k =0.4 N/m
and nominal tip radius of 2 nm. One drop (10 µL) of dendrimer solution (400 µg/mL in PBS pH
7.4) was placed on a freshly cleaved mica surface and was left to dry at 20 oC overnight,
protected from light, before measurements. All images were analyzed using NanoScope Analysis
1.5 software (Bruker, Santa Barbara, CA). Height images were corrected by first order flattening.

Evaluation of redox sensitivity of the dendrimer-based vesicles
Size measurement
The hydrodynamic diameter was measured at different time intervals by dynamic light scattering
as described above for low- and high-cholesterol dendrimer-based vesicles (1.5 mL, 100 µg/mL
in PBS pH 7.4), incubated with or without glutathione (10 µm and 10 mM) at 37 oC. Sample
solutions in presence and absence of glutathione were prepared by mixing 75 μL of stock
dendrimer solutions (2 mg/mL) with 150 μL glutathione solution (100 mM or 100 μM) and 1275
μL PBS (pH 7.4), or 1425 μL PBS solution (pH 7.4) for control measurement. The samples were
then incubated in the dark under stirring at 37 oC for 48 h.

14

Redox-sensitive release of Nile Red from the vesicles
The redox-triggered release of an entrapped lipophilic dye, Nile Red, from the low- and highcholesterol dendrimer-based vesicles was assessed using the reducing agent glutathione.
In order to entrap Nile Red into the vesicles, low- and high-cholesterol dendrimer-based
vesicles (2 mg/mL) were prepared in PBS (pH 7.4) and equilibrated for 24h at 20 oC. Nile Red
solution (40 μL, 5 mg/mL in methanol) was added into an empty plastic vial and the methanol
was evaporated by a stream of N2 gas. Then, 1 mL of stock dendrimer-based vesicles was added
to the vial containing Nile Red and the mixed dispersion was stirred at 20 oC for 40 h, protected
from light. The dispersions were then filtered through hydrophilic cellulose acetate membranes
with pore size of 0.45 μm to remove free Nile Red.
To test the glutathione-sensitive release of entrapped Nile Red from the vesicles, 75 μL of Nile
Red-entrapped vesicles (2 mg/mL) were mixed with either 1425 μL PBS for control
measurement, or 150 μL glutathione solutions (100 mM or 100 μM) and 1275 μL PBS to get the
experimental concentration in absence and presence of glutathione. Fluorescence spectra of Nile
Red were recorded (λex: 540 nm, λem: 560-800 nm, excitation and emission slits at 10 nm and 20
nm respectively) at different time intervals, considering the addition of glutathione solution as
the start of the experiment.

Characterization of dendriplex formation
Evaluation of DNA condensation
The ability of cholesterol-bearing dendrimers to complex negatively charged plasmid DNA
encoding β-galactosidase was evaluated by a PicoGreen® assay, performed according to the
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supplier's protocol. On the day of the experiment, PicoGreen® reagent was diluted 200-fold in
Tris–EDTA (TE) buffer (10 mM Tris, 1 mM EDTA, pH 7.5). DNA solution (500 μL, 10 μg/mL
in TE buffer) was added to each sample of dendrimer solution (500 μL in TE buffer) and
vortexed to prepare 1 mL of dendrimer: DNA complexes, with dendrimer: DNA weight ratios of
20:1, 10:1, 5:1, 2:1, 1:1, 0.5:1 and 0:1. One mL PicoGreen® solution was then added to the
dendriplexes and vortexed immediately before the first measurement. The fluorescence intensity
of PicoGreen® (λex: 480 nm, λem: 520 nm, excitation and emission slits: 5 nm each) in presence
of the dendriplexes was measured at various times using a Varian Cary Eclipse Fluorescence
spectrophotometer (Palo Alto, CA). Results were represented as percentage of DNA
condensation.
Agarose gel retardation assay was also performed to assess DNA condensation ability of the
dendrimers. Dendriplexes were prepared at various dendrimer: DNA weight ratios from 20:1 to
0.5:1, with a constant DNA concentration of 20 µg/mL. After mixing with the loading buffer (2
µL), the samples (10 µL) were loaded on a 1X Tris-Borate-EDTA (TBE) (89 mM Tris base, 89
mM boric acid, 2 mM Na2-EDTA, pH 8.3) buffered 0.8% (w/v) agarose gel containing ethidium
bromide (0.4 µg/mL), with 1x TBE as a running buffer and HyperLadder 1Kb as a DNA size
marker. The gel was run at 50 V for 1 h and then photographed under UV light.

Size and zeta potential measurement
Hydrodynamic diameter and zeta potential of dendriplexes was measured by dynamic light
scattering (DLS) using a Malvern Nano ZS instrument (Malvern Instruments, Malvern, UK),
immediately after mixing a fixed amount of DNA (50 µg) to various dendrimer concentrations in
5% glucose solution (dendrimer: DNA weight ratios: 0.5:1, 1:1, 2:1, 5:1, 10:1 and 20:1).
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Observation of the morphology of the dendriplexes
The morphology of the dendriplexes was observed using TEM as described above at an
accelerating voltage of 80 kV. Three µL of each dendriplex solution in PBS (pH 7.4) was drop
cast on a carbon-coated copper grid (400 mesh size) instantaneously after mixing of a fixed
amount of DNA (50 µg) to various dendrimer concentrations (dendrimer: DNA weight ratios:
5:1 and 10:1). The grid was then kept in a desiccator overnight for drying before imaging.

In vitro analysis
Cell culture
Human prostate adenocarcinoma PC3M-Luc cells were grown as monolayers in Minimum
Essential Medium (MEM), supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) Lglutamine and 0.5% (v/v) penicillin–streptomycin. Cells were cultured at 37 °C in a 5% carbon
dioxide, humid atmosphere.

Evaluation of cell viability
The cell viability of modified dendrimers was evaluated using a standard MTT assay. To this
end, PC-3 cells were seeded at a density of 5 000 cells per well in 96-well plates and grown at 37
°C for 24 h in a 5% carbon dioxide, humid atmosphere. They were then treated with different
concentrations of dendrimer solution (ranging from 5 to 45 µg/mL) for various incubation time
(24, 48 and 72 h). Following treatment, 50 µL of MTT solution (5 mg/mL in PBS pH 7.4) was
added in each well and incubated for 4 h at 37 °C. Medium was then removed and 200 µL
DMSO was added in each well to solubilize the formazan dye produced during the reduction of
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MTT by the living cells. The amount of formazan dye was measured using spectrophotometry at
540 nm with a Multiskan Ascent® plate reader (Thermo Scientific, Waltham, MA).

Cellular uptake of dendriplexes
Qualitative analysis
The cellular uptake of low-and high-cholesterol, dendrimer-based vesicles complexed to DNA
was qualitatively assessed using confocal microscopy. Labeling of plasmid DNA with the
fluorescent probe fluorescein was performed using a Label IT® Fluorescein Nucleic Acid
Labeling kit, as described by the manufacturer. PC-3 cells were seeded on coverslips in 6-well
plates at a concentration of 105 cells per well and grown for 48 h at 37 °C. The cells were then
treated with fluorescein-labelled DNA (2.5 µg/well) complexed to low-and high-cholesterol
vesicles, at a dendrimer: DNA weight ratios of 5:1 and 10:1 for 2 hours at 37 °C. Control wells
were also prepared with naked DNA or remained untreated. The cells were then washed three
times with 3 mL phosphate buffered saline (PBS) before being fixed with 2 mL methanol for 10
min at 20 oC. They were then washed again with 3 mL PBS. Upon staining of the nuclei with
Vectashield® mounting medium containing DAPI, the cells were examined using a Leica TCS
SP5 confocal microscope (Wetzlar, Germany). DAPI (which stained the cell nuclei) was excited
with the 405 nm laser line (emission bandwidth: 415-491 nm), fluorescein (which labelled the
DNA) was excited with the 514 nm laser line (emission bandwidth: 550-620 nm).

Quantitative analysis
Quantification of cellular uptake of the dendrimer-based vesicles complexed to DNA was carried
out by flow cytometry. PC-3 cells were seeded at a density of 105 cells per well in 6-well plates
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and grown at 37 °C for 72 h, before being treated fluorescein-labeled DNA (2.5 µg DNA/well)
complexed with the vesicles at dendrimer: DNA weight ratios of 5:1 and 10:1. Other wells were
treated with DAB dendriplex and DNA solution as positive and negative controls respectively.
After 2 h incubation with the treatments, single cell suspensions were prepared (using 250 µL
trypsin per well, followed by 500 µL medium per well once the cells have detached), before
being analyzed using a FACSCanto® flow cytometer (BD, Franklin Lakes, NJ). Their mean
fluorescence intensity was analyzed with FACSDiva® software (BD, Franklin Lakes, NJ),
counting ten thousand cells (gated events) for each sample.

Evaluation of gene expression of the DNA complexed with the dendrimer-based vesicles
The transfection efficacy of the DNA complexed by the dendrimer-based vesicles was assessed
using a plasmid DNA encoding β-galactosidase (pCMV β-gal). PC-3 cells were seeded at a
concentration of 2 000 cells/well in 96-well plates and left to grow for 72 h at 37 °C in a 5% CO2
atmosphere. They were then treated with the complex in quintuplicate at various dendrimer:
DNA weight ratios (20:1, 10:1, 5:1, 2:1, 1:1 and 0.5:1). Naked DNA was used as a negative
control and DAB-DNA (dendrimer: DNA weight ratio 5:1) served as a positive control. DNA
concentration (1 µg/mL) was kept constant throughout the experiment. After treatment, the cells
were incubated for 24 h, 48 h and 72 h before analysis. They were then lysed with 1X passive
lysis buffer (PLB) (50 µL/well) for 20 min at 37 oC and then tested for β-galactosidase
expression. Briefly, 50 µL of the assay buffer (2 mM magnesium chloride, 100 mM
mercaptoethanol, 1.33 mg/mL O-nitrophenyl- β-D-galactosidase, 200 mM sodium phosphate
buffer, pH 7.3) was added to the cell lysates and incubated for 2 h at 37 oC. The absorbance of
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the samples was subsequently read at 405 nm using a Multiskan Ascent ® plate reader (MTX Lab
Systems, Brandenton, FL).

Statistical analysis
Results were expressed as means ± standard error of the mean. Statistical significance was
assessed by one-way analysis of variance and Tukey multiple comparison post-test (Minitab®
software, State College, PE). Differences were considered statistically significant for P values
lower than 0.05.
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RESULTS AND DISCUSSION
Synthesis and characterization of the disulphide-linked cholesterol-bearing PEGylated
dendrimers
The synthesis of low- and high-cholesterol disulphide-linked PEGylated dendrimers was
confirmed by FTIR, 1H-NMR and MALDI-TOF MS. Infrared (ATR) spectra of low-and highcholesterol dendrimers (Figure S1) showed the presence of a new peak at 1645-1646 cm-1
(corresponding to an amide bond) and the absence of a peak at 1719-1740 cm-1 (corresponding to
the succinimidyl carboxymethyl ester group), in comparison with that of the starting materials
OPSS-PEG-SCM DAB-G3 and CHOLSH (Figure S2), thus demonstrating the conjugation of
PEG to DAB through amide bond formation.
The conjugation of cholesterol and PEG to DAB was also confirmed by 1H-NMR, as follows:
1

H-NMR (CDCl3): δ2.39-2.43 ppm, DAB (N-CH2-CH2-CH2-N) (a); δ2.44-2.46 ppm, DAB (N-

CH2-CH2-CH2-NH2) (b); δ3.98 ppm, PEG (NH-CO-CH2-OCH2CH2) (c); δ5.35-5.36 ppm,
cholesterol (C=CH-CH2) (d); δ0.67 ppm, cholesterol (CH2CCH3-CH-CH2CH2CCH3) (e) (Figure
S3).
Molecular weights of both low- and high-cholesterol dendrimers were assigned using MALDITOF mass spectrometry (Figure S4). Both mass spectra mainly exhibited singly charged
molecular ions [M]+ with their fragmented products. The average molecular weight of lowcholesterol PEGylated DAB was 4210 Da, indicating that the ratios of conjugated PEG as well as
cholesterol per dendrimer were nearly 1. The average molecular weight of its high-cholesterol
counterpart was 6492 Da, demonstrating that these ratios were nearly 2 (Figure S4). MALDI-
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TOF mass spectrometry data was analyzed to calculate the percentage of conjugated lipid to
dendrimer, which were 9.5% for the low-cholesterol dendrimer and 12.5% for the highcholesterol dendrimer.
Both low-and high-cholesterol dendrimers showed relatively low % yield (respectively 43% and
33% for low- and high-cholesterol dendrimers).

1

H NMR spectrum of high-cholesterol dendrimer in D2O showed the peaks of DAB and

PEG, but no peak for cholesterol (Figure S5), unlike the NMR spectrum of high-cholesterol
dendrimer in CDCl3, where peaks for cholesterol were visible (Figure S3B). The absence of the
NMR peaks for cholesterol in D2O and the reappearance of these peaks in CDCl3 demonstrated
the amphiphilic nature of the modified dendrimer with a possible self-organization tendency to
form self-assembled nano- or microstructure in aqueous medium.
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The two-step in situ

synthetic procedure applied in this study allowed the successful conjugation of PEG and
cholesterol on one amine group, which helped to retain more primary amine groups on the
surface of the dendrimers and is crucial for the complexation of nucleic acids.

Evaluation of the self-assembly formation of the dendrimers
To study the possible self-assembly of the low-and high-cholesterol PEGylated amphiphilic
dendrimers, steady-state fluorescence technique using NPN as probe molecule was used. Being a
hydrophobic fluorescent probe, NPN is weakly fluorescent in water, but its fluorescence intensity
increases when it is being solubilized in a non-polar medium or within the hydrophobic core of
any self-assembled aggregates.
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The fluorescence intensity of NPN exhibited a gradual rise of
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fluorescence with increasing concentrations of dendrimer in PBS (pH 7.4) with a complete blue
shift of the λmax (from ~465 nm at a dendrimer concentration of 0 µg/mL to ~420 nm at a
dendrimer concentration of 400 µg/mL) (Figure S6), demonstrating the solubilization of the
probe in the hydrophobic domain of the self-assembled aggregate formed by these amphiphilic
dendrimers. The initial plateau of the curve showed concentration-independent fluorescence
intensity for dendrimer concentrations below 10 µg/mL, which reveals that self-association of
the dendrimers starts through the inter-chain aggregation above the critical aggregate
concentration, without formation of unimer aggregates (Figure 1). The critical aggregation
concentration (CAC) values were calculated from the inflection point of the plot of relative
fluorescence intensities (I/Io, where I and Io are respectively the fluorescence intensities in the
presence and absence of dendrimer) of NPN at various dendrimer concentrations (Figure 1). The
CAC values decreased by increasing the degree of cholesterol conjugation: the high-cholesterol
dendrimer had a comparatively lower CAC value (~10 µg/mL) than that of the low-cholesterol
dendrimer (~21 µg/mL). This might be attributed to the overall higher hydrophobe content of the
high-cholesterol dendrimer in comparison with the low-cholesterol dendrimer, as the selfassembled aggregate formation occurs mainly through the hydrophobic interaction among the
lipid molecules. The CAC values for the low and high cholesterol-modified PEGylated
dendrimers were found to be close to that obtained with generation 1-, generation 2- and
generation 3-PAMAM dendrimer conjugated to cholesterol at 40% mole ratio of
cholesterol/primary amine (12.5 ± 3.2 µg/mL for generation 2-PAMAM-cholesterol, 28.9 ± 4.1
µg/mL for generation 1-PAMAM-cholesterol and 28.7 ± 3.5 µg/mL for generation 3-PAMAMcholesterol).
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They were lower than the CMC observed when using generation-3 PAMAM

dendrimers conjugated to cholesterol at 6% and 15% mole ratio of cholesterol/primary amine
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(respectively 86.6 ± 5.6 µg/mL and 50.2 ± 5.1 µg/mL).
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These low CMC facilitated the

incorporation of the PAMAM-cholesterol in the PEG-stabilized liposome bilayer. In addition,
the CAC values for the low- and high-cholesterol dendrimers were found to be well below those
of dendrimersomes and glycodendrimersomes prepared from self-assembling amphiphilic Janus
dendrimers (typically between 0.5 mg/mL and 1 mg/mL).
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The CAC values obtained in our

experiments were low, indicating the stability of the self-assemblies in dilute conditions, which
is a very important parameter for future applications as drug and gene delivery systems.
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Figure 1. Relative fluorescence intensity (I/Io) of N-Phenyl-1-naphthylamine in function of the
concentration of low-cholesterol dendrimer (A, R2: 0.99) and high-cholesterol dendrimer (B, R2:
0.96) in PBS buffer (pH 7.4)
25

Hydrodynamic size and zeta potential of dendrimer self-assembled nanostructures
Both low-cholesterol and high-cholesterol dendrimer-based self-assembled nanostructures
displayed an average size less than 230 nm at all the concentrations tested, with low
polydispersity index (PDI) values (respectively 0.25-0.4 and 0.2-0.25 for low and high
cholesterol dendrimer-based nanostructures) (Figure 2). Their size gradually decreased from low
to high concentrations, to reach their smallest sizes of 91.3 nm ± 11.3 nm and 133.4 nm ± 48.8
nm respectively for low-cholesterol and high-cholesterol dendrimer-based nanostructures. This
decrease might be due to the formation of more compact and stable nanostructures at high
concentrations, resulting from increased hydrophobic interactions among cholesterol at higher
dendrimer concentrations. These sizes were generally lower than those reported for spontaneous
or stimuli-sensitive, dendrimer-based vesicular structures made of C17 and C18 alkyl chainbearing polyamine amphiphilic dendrimers, that ranged from 200 to 500 nm.
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Furthermore,

they were below the cut-off size for extravasation, which is 400 nm for most tumors. 35
Zeta potential experiments demonstrated that these self-assembled nanostructures were bearing
a positive zeta potential comprised between 4 mV and 7 mV for both dendrimers. Zeta potential
increased with increasing concentrations, to reach maximum values of 5.7 mV ± 0.5 mV and 6.5
mV ± 0.3 mV respectively for low-cholesterol and high-cholesterol dendrimer-based
nanostructures. It was similar as that obtained with disulphide cross-linked hyperbranched
PAMAM-based vesicles (~5 mV). 36 These positively charged formulations would increase their
electrostatic interactions with the negatively charged cellular membranes, resulting in an
enhanced cellular uptake of the nanostructures through internalization mechanisms.

37

The

modulation of the amount of cholesterol within the dendrimers did not impact on the size and
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zeta potential of the low-cholesterol and high-cholesterol dendrimer-based self-assembled
nanostructures, that were no statistically different at all measured concentrations.

Figure 2. Size (A) and zeta potential (B) of low-cholesterol (■) and high-cholesterol (○)
dendrimers self-assembled nanostructures in PBS buffer (pH 7.4) at 37 oC
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Formation of low-and high-cholesterol dendrimer-based vesicles
Observation of the morphology of the self-assembled nanostructures
TEM images of the low-and high-cholesterol dendrimer-based nanostructures revealed the
presence of spherical unilamellar vesicles. Their size (lower than 50 nm) was smaller than that
observed with DLS, as TEM images were taken following drying of the samples, unlike DLS,
where hydrodynamic sizes were being measured.

Encapsulation of hydrophilic dye R6G by the self-assembled nanostructures
Normalized fluorescence spectra of the cationic hydrophilic dye R6G showed the quenching of
the fluorescence intensity of the dye in presence of the dendrimer-based vesicles, compared with
that of absorbance-matched dye solution (Figure 3). As R6G dye exhibits self-quenching
properties, it is possible to investigate whether it is sequestered inside a vesicle-type
nanostructure. When a certain amount of hydrophilic dye, R6G is uniformly distributed in water,
it fluoresces without any self-quenching effect. However, when some of the dye is being
encapsulated within the aqueous core of the dendrimer-based vesicles, the local concentration of
the dye within this small-volume core increases, leading to self-quenching.
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These results

therefore demonstrated the encapsulation of R6G in the aqueous core of the dendrimer-based
vesicles, with drug loading efficiencies of 0.28 % and 0.20 % respectively for the low-and highcholesterol dendrimer-based vesicles. This further confirms that the structure of the selfassembly nanostructure is a vesicle, and not a micelle, as a micelle would not be able to entrap
hydrophilic dyes.
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Figure 3. Demonstration of the formation of low- and high-cholesterol dendrimer-based
vesicles:
- Unstained TEM images of low-cholesterol (A) and high-cholesterol (C) dendrimer-based
vesicles (400 µg/mL in PBS, pH 7.4)
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- Normalized fluorescence spectra of R6G in the presence and absence of low-cholesterol (B)
and high-cholesterol (D) dendrimer-based vesicles (400 µg/mL in PBS, pH 7.4)

Thermal analysis of phase transition behavior of low-and high-cholesterol dendrimer-based
vesicles
Thermal stability at physiological conditions (pH 7.4, 37 oC) is an important parameter for drug
delivery carriers. Percent transmittance (%T) with increasing temperature (Figure S7) showed
more than 95% transmittance for both low-cholesterol and high-cholesterol dendrimer-based
vesicles (400 µg/mL in PBS buffer pH 7.4), suggesting there was no lower critical solution
temperature (LCST) or cloud point (CT) in temperature ranging from 20 to 90 ○C. These results
demonstrated that there should be no phase separation of dendrimer-based vesicles at body
temperature (37 oC) and therefore no premature release of any entrapped pharmaceutically active
agent at body temperature. The cationic nature and PEGylation of both cholesterol-modified
amphiphilic dendrimers make them more hydrophilic and stable in water at even higher
temperatures at this concentration in comparison with cholesterol-based PEGylated polymers
(LCST~57-65 oC) or high molecular-weight PEGylated biaryl-based amphiphilic dendrons
(LCST~31-42 oC). 18,39
To investigate the impact of the steroidal lipid molecule on the backbone structure of the
PEGylated dendrimers, differential scanning calorimetry was performed. An endothermic
melting peak (Tm) was visible at nearly 0 °C (-0.6 °C and -0.8 °C respectively for lowcholesterol and high-cholesterol dendrimer-based vesicles) during the heating phase. It also
appeared during the second heating cycle (Figure 4). This melting peak (Tm) of heating is
responsible for the phase change of the vesicle membrane, from “gel” state to “liquid crystalline”
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or “fluid” state, which is similar to that of another unsaturated lipid-based liposomal formulation,
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC; Tm= ‒2 oC).

40-41

The presence of

unsaturation in cholesterol and/or in the disulphide bond might be the reason for such low Tm.
Although both dendrimer-based vesicles showed nearly the same melting peak, the melting
enthalpy (area under the endothermic melting curve) decreased to a lower value from highcholesterol to low-cholesterol vesicles (Table S1), due to a progressive ‘‘dilution’’ of the lipids
(cholesterol) in the membrane from high-cholesterol to low-cholesterol dendrimer-based
vesicles. 41

Figure 4. DSC spectra of low-cholesterol (DSPCL, red) and high-cholesterol (DSPCH, blue)
dendrimers for the first heating (2 °C.min−1) and second heating cycles (2 °C.min−1)
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AFM imaging of vesicular aggregates
AFM images were recorded for both dendrimer-based vesicles in PBS (pH 7.4) adsorbed after air
drying on freshly cleaved mica surface. Low-cholesterol, dendrimer-based vesicles kept their
vesicular structure, but their shape was slightly deformed and changed from spheres to spherical
caps, as seen in the cross-section analysis (Figure 5). This was probably due to the strong
adsorption of lipid-bearing dendrimer onto the freshly cleaved mica surface, which was also the
reason behind the broadening of their diameter. The effect of adsorption of the vesicles onto
mica surface was even enhanced in the case of high-cholesterol dendrimer-based vesicles, whose
dendrimers contain a larger amount of lipids. This led to a more pronounced deformation of the
high-cholesterol vesicles and a wider spreading of these vesicles on the mica surface (Figure 5).
42-43

By comparison, the preparation of TEM carbon grids resulted in a much limited deformation

of the vesicles, due to the lower surface energy of these grids, whereas the vesicles were
subjected to pronounced deformation when in contact with the mica surface, even leading to
fusion, as reported for some liposomes and polymersomes.

42-43

The spherical caps had an

average typical height of about 20 nm and 10 nm respectively for low-cholesterol and highcholesterol dendrimer-based vesicles, which further corroborates the spreading of the highcholesterol vesicles, producing an almost flat film on the mica surface because of their higher
lipid content. 42-43
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Figure 5 Tapping mode AFM phase and height contrast images of 5 x 5 μm surfaces of lowcholesterol (A, B) and high-cholesterol (D, E) dendrimer-based vesicular solution (400 µg/mL)
adsorbed on a mica (silicon) surface. The average heights were measured by cross section
analysis for low-cholesterol (C) and high-cholesterol (F) vesicles, revealing the shape of a
spherical cap.

Evaluation of redox sensitivity of the dendrimer-based vesicles
Size measurement
The bilayer of the dendrimer-based vesicles is composed of hydrophobic cholesterol, which is
conjugated to the PEGylated dendrimer via a disulfide linkage sensitive to the reducing agent
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glutathione (Scheme 2). The redox-responsiveness of these vesicles was investigated by
monitoring the changes in the hydrodynamic sizes of the vesicles via dynamic light scattering
measurements in presence or absence of glutathione at different time intervals and at different
glutathione concentrations (10 µM and 10 mM, corresponding to reducing environments in the
extracellular and intracellular compartments respectively).

Scheme 2. Schematic representation of the formation of vesicles by both low-cholesterol and
high-cholesterol DAB-PEG-S-S-CHOL dendrimers, showing encapsulation of hydrophilic and
hydrophobic drugs respectively in the aqueous core and hydrophobic bilayer.

Low-cholesterol vesicles displayed similar sizes (less than 200 nm) in presence of 10 µM or
without glutathione at all the tested durations. However, a higher concentration (10 mM) of
glutathione induced a pronounced increase in size from 9 h (104.3 ± 15.2 nm) to 48 h (716.3 ±
16.1 nm), therefore demonstrating that the vesicles have disintegrated at that time (Figure 6A).
A similar trend was also observed for the high-cholesterol vesicles in presence of 10 mM
glutathione from 9 h (155.1 ± 66.1 nm) to 48 h (771.1 ± 28.2 nm) although the vesicle size at 24
34

h (240.3 ± 78.3 nm) was lower than that observed with low-cholesterol vesicles (331.3 ± 37.2
nm) (Figure 6B). This increase in size can be attributed to the cleavage of the disulfide bonds and
disintegration of the vesicles, forming larger, unstable and less compact aggregates. The highcholesterol PEGylated dendrimer, having a larger amount of cholesterol and larger number of
disulfide linkages than its low-cholesterol counterpart, may allow a more limited access for the
hydrophilic glutathione to its lipidic bilayer (thus explaining the size differences at 24 h) and
may require a larger amount of glutathione to break the excess disulphide bonds than lowcholesterol dendrimer. Both low-and high-cholesterol vesicles expressed strong redox sensitivity
in presence of 10 mM glutathione, corresponding to reducing environment in the intracellular
compartment. These effects were similar to those observed for redox-responsive PEGylated
generation 4-PAMAM dendrimers (that show a significant decrease of particle size from 16.9 ±
0.8 nm to 12.5 ± 0.5 nm occurring in presence of 10 mM glutathione)41 and disulphide crosslinked hyperbranched PAMAM dendrimer-based vesicles, whose size changed from 110 nm to
23 nm in presence of 10 mM dithiothreitol. 36
The sizes of vesicles incubated in PBS with or without 10 µM glutathione were almost the
same even 48 h after the start of the experiment, implying that the extracellular reducing
environment has little effect on the integrity of the vesicles. However, the intracellular or
cytosolic reducing environment (corresponding to 10 mM glutathione) has a massive impact on
the disassembly of the vesicles, raising the possibility of future use of these dendrimer-based
vesicles as redox-responsive drug delivery systems for cancer treatment, as cancer cells have
even further elevated intracellular glutathione concentration.
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Figure 6. Evaluation of gluthatione sensitivity of the dendrimer-based vesicles:
- Hydrodynamic size distribution of low-cholesterol (A) and high-cholesterol (B) dendrimerbased vesicles (100 µg/mL in PBS, pH 7.4) at different time intervals, in presence or in absence
of glutathione (GSH) (10 µM and 10 mM) at 37 oC (n=3)
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- Fluorescence emission spectra of Nile Red in PBS (pH 7.4) (C), alone or in presence of lowcholesterol (DPSCL) and high-cholesterol (DPSCH) dendrimer-based vesicles (100 µg/mL in
PBS, pH 7.4)
- Release profile of Nile Red (D) from low-cholesterol (DPSCL) and high-cholesterol (DPSCH)
dendrimer-based vesicles (100 µg/mL in PBS, pH 7.4), in absence or presence of GSH (10 µM
and 10 mM) at different time intervals.

Redox-sensitive release of Nile Red from the vesicles
The successful entrapment of Nile Red in the bilayer of the vesicles (with drug loading
efficiencies of respectively 0.14 % and 0.17 % for low- and high-cholesterol dendrimer-based
vesicles) was shown by an increase in fluorescence intensity of Nile Red in presence of the
vesicles (543, 703 and 10 fluorescence arbitrary units respectively with low-cholesterol vesicles,
high-cholesterol vesicles and free Nile Red solution), with a concomitant blue shift of 24 nm for
λmax of the entrapped dye (λmax: 632 nm) compared to the free solution (λmax: 656 nm) (Figure
6C). The increased fluorescence intensity observed in the presence of high-cholesterol vesicles
might be attributed to the higher cholesterol content of these vesicles, thus facilitating the
entrapment of the lipophilic dye in the lipid bilayer of the vesicles.
In presence of glutathione, a tripeptide having a free thiol, the vesicle bilayers are expected to
be disassembled due to thiol-disulphide reaction, with a concomitant release of the encapsulated
Nile Red.45 This naturally occurring biological thiol is present at different concentrations in
extracellular (10 µM) and intracellular (10 mM) compartments. The fluorescence intensity of the
entrapped Nile Red was monitored in function of time in presence or absence of glutathione (10
µM and 10 mM). The fluorescence intensity of Nile Red entrapped in low-cholesterol- and high-
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cholesterol-vesicles sharply decreased in presence of 10mM glutathione (Figure S8). This effect
was most pronounced at 48 h after the start of the incubation with the low-cholesterol vesicles
(299 and 486 arbitrary units for Nile Red respectively entrapped in low-and high-cholesterol
vesicles). The decrease of fluorescence intensity was also observed in the presence of 10 µM
glutathione, but to a lesser extent (453 and 620 arbitrary units for Nile Red respectively
entrapped in low-and high-cholesterol vesicles at 48 h).
The cumulative release profile of Nile Red from the vesicles in presence or absence of
glutathione indicated that both vesicles are more fragile in intracellular redox conditions rather
than in extracellular conditions, leading to a higher and faster release of Nile Red in more
reductive conditions (up to 40% and ~ 25% Nile red release from respectively the lowcholesterol and high-cholesterol dendrimersomes in presence of 10 mM glutathione) (Figure
6D). Although both low- and high-cholesterol vesicles showed a sustained release of the dye, the
high-cholesterol vesicles having more disulphide-conjugated lipophilic units were more resistant
to higher glutathione concentration, resulting in a lower release of the guest compared to its lowcholesterol counterpart. The sustained release of the hydrophobic Nile Red dye may be due to the
limited access of the hydrophilic glutathione to the highly hydrophobic and compact bilayer
region of the vesicles and would be advantageous for the slow release of a drug in conjunction
with an associated therapeutic entity with a faster release, such as therapeutic nucleic acid. These
results were close to that observed with redox-sensitive PEGylated amphiphilic methacrylatebased polymeric nanoassemblies without any cholesterol (up to 40% Nile Red release when in
presence of 10 mM glutathione). 45
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Characterization of dendriplex formation
Evaluation of DNA condensation
The cholesterol-bearing PEGylated dendrimers can efficiently bind to negatively charged
DNA through electrostatic interactions between the protonated primary amines of the dendrimers
and the negatively charged phosphodiester groups of the DNA to form dendrimer: DNA
complexes (dendriplexes). The fluorescence of PicoGreen® significantly increases on
intercalation with double stranded DNA. The electrostatic interactions between the negatively
charged DNA and positively charged dendrimers on formation of the dendriplex condense the
DNA and reduce the number of PicoGreen® binding sites, resulting in a decrease in the
fluorescence intensity of the PicoGreen® solution.
Both low-cholesterol and high-cholesterol dendrimers were able to condense more than 85%
of the DNA at all tested ratios for the low-cholesterol dendrimer, and at dendrimer: DNA weight
ratios of 1:1 and higher for the high-cholesterol dendrimer, which displayed less primary amines
at its periphery than its low-cholesterol counterpart (Figures 7A and B). DNA condensation
occurred instantly and was found to be stable for at least 24 h. DNA condensing ability of these
modified dendrimers was of the same range to that reported for generations 1, 2 and 3-PAMAM
dendrimers conjugated to 40% cholesterol,
lipids-based lipoplexes,

16

30-31

PEGylated poly(amidoamine) dendron-bearing

octadecyl alkyl chain-bearing generations 2- and 3- PAMAM

dendrons forming lipoplexes following probe sonication
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(up to 100% for all of these

formulations).
A gel retardation assay confirmed the complete and partial DNA condensation by cholesterolbearing dendrimers (Figures S9 and S10). At dendrimer: DNA weight ratios higher than 1:1,
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DNA was fully condensed by cholesterol-bearing DAB, thus preventing ethidium bromide to
intercalate with DNA. No free DNA was therefore visible at these ratios.
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Figure 7. Evaluation of the DNA complexation of the low-cholesterol and high-cholesterol
dendrimers:
- DNA condensation of low-cholesterol (A) and high-cholesterol (B) dendriplexes using
PicoGreen® reagent at various durations and dendrimer: DNA weight ratios: 20:1 (■, black),
10:1 (●, red), 5:1 (▲, blue), 2:1 (▼, magenta), 1:1 (♦, green) and 0.5:1 (◄, violet). Results are
expressed as mean ± SEM (n=4)
- Size (C) and zeta potential (D) of low-cholesterol (○) and high-cholesterol (■) dendriplexes at
various dendrimer: DNA weight ratios, in 5% glucose at 37 oC (n=3)
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Size and zeta potential measurement
Low-cholesterol dendriplex displayed an average size lower than 150 nm at all dendrimer:
DNA weight ratios used, with a low polydispersity index (0.15 to 0.3). By contrast, the size of
high-cholesterol dendriplex initially decreased with increasing dendrimer: DNA weight ratios
ranging from 0.5:1 to 5:1 (from 127.6 ± 3.7 nm to 95.8 ± 4.2 nm) due to the increase in
hydrophobicity, as previously described in the case of cholesterol modified sperminefunctionalised dendrons. 47 It then increased to reach a maximum of 320.8 ± 70.2 nm at a ratio of
20:1 which might be due to losing its hydrophobic balance (Figure 7C).
Overall, dendriplexes showed a smaller hydrodynamic diameter due to the presence of the
highly hydrophobic cholesterol in the backbone, leading to the formation of more compact
dendriplexes in comparison to not only C18 alkyl chain-modified generation 3- PAMAM
dendrimers, but also cholesterol-modified generations 1, 2 and 3- PAMAM-based
dendriplexes.16,30-31 Both low-cholesterol and high-cholesterol dendriplexes presented an overall
average size lower than the unmodified DAB dendriplex, which had an average size of 196 nm
(polydispersity index: 0.683).

8

This smaller size will further facilitate their extravasation to

cancer cells.
Zeta potential experiments demonstrated that the dendriplexes were bearing slightly increasing
positive surface charge comprised between 21.4 ± 0.9 and 41.1 ± 0.6 mV for most ratios, but a
negative charge of around ‒20 mV at a dendrimer: DNA weight ratio of 0.5:1. There was no
significant differences of results between low- and high-cholesterol dendriplexes (Figure 7D).
These dendriplexes showed a much higher positive zeta potential in comparison with PEGylated
poly(amidoamine) dendron-bearing lipids-based lipoplexes (~4-10 mV)
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and with generations
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1, 2 and 3-PAMAM dendrimers conjugated to 40% cholesterol (~18-23 mV).30-31 This increased
zeta potential would therefore further facilitate the uptake of these dendriplexes by cancer cells.

Observation of the morphology of the dendriplexes
Transmission electron microscopic images showed the presence of dendrimer-based vesicles
even after complexation with DNA, at dendrimer: DNA weight ratios 5:1 and 10:1 (Figure 8).
Both the dendrimers have retained their ability to form vesicles with sizes lower than 100 nm in
presence of DNA, unlike other C17 alkyl chain-modified polyamine-based dendrimersomes that
transformed from vesicular forms to micellar structures in presence of siRNA.34 Low-cholesterol
vesicles appeared to form smaller vesicles at a ratio 5:1 than at a ratio 10:1, unlike the highcholesterol vesicles that seemed to be of similar size at both ratios.
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Figure 8. Unstained TEM images of low-cholesterol (A and B) and high-cholesterol (C and D)
dendriplexes at dendrimer: DNA weight ratios of 5:1 (A and C) and 10:1 (B and D)
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In vitro analysis
Evaluation of cell viability
The viability of PC-3 cells following treatment with low-cholesterol vesicles was maintained
up to a dendrimer concentration of 40 µg/mL for 24 h incubation (58.7 ± 12.6 % viability) and
25 µg/mL for 48 h and 72 h incubation (64.5 ± 11.1 and 56.7 ±17.6 % viability respectively)
(Figure 9A).
Replacing low-cholesterol dendrimersomes with high-cholesterol dendrimersomes led to a
decrease in cell viability, which remains constant up to a dendrimer concentration of 35 µg/mL
for 24 h and 48 h incubation (71.9 ± 10.4 and 66.4 ± 11.4 % viability respectively) and 40 µg/mL
for 72 h incubation (66.4 ± 8.9 % viability) (Figure 9B). Similar cell viability was observed
following treatment of HeLa-Luc cells and Huh-7-Luc cancer cell lines with cationic PAMAM
dendron-bearing lipids (more than 70% viability up to 32 µg/mL after 48 h).
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Low- and high-

cholesterol dendrimersomes led to an improved cell viability compared with cholesterolmodified generations 3- and 5- PAMAM dendrimers

49

, which might be due to the presence of

PEG and comparatively lower amount of cholesterol in the backbone.
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Figure 9. Cell viability of the low-cholesterol (A) and high-cholesterol (B) dendrimers on PC3
prostate cancer cells at various concentrations and treatment durations (n=6) (* : P <0.05
compared with dendrimer concentration at t= 0 h)
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Evaluation of gene expression of the dendrimers complexed with DNA
Both low-and high-cholesterol dendrimers complexed to DNA led to gene transfection at all the
durations tested on PC3 cell line with different amounts (Figure 10). The highest transfection
level following treatment with low-cholesterol dendrimer complex was obtained at dendrimer:
DNA weight ratio of 5:1 after 72 h treatment. At this ratio, gene expression was 4.92-fold higher
than following treatment with DNA (1.30 ± 0.07 U/mL), but 1.33-fold lower than with DAB
dendriplex (8.55 ± 0.64 U/mL).
When replacing low-cholesterol dendrimer by high-cholesterol dendrimer, the highest gene
expression resulted from treatment with the dendrimer complex at a ratio of 10:1, after 72 h
treatment. It was 4.98-fold higher than following treatment with DNA (1.2 ± 0.15 U/mL), 1.26fold lower than with DAB dendriplex (7.59 ± 1.38 U/mL), and similar to the highest gene
expression obtained with its low-cholesterol counterpart. Treatment with naked DNA only
resulted in weak levels of gene expression, as expected. Both cholesterol-modified DABdendriplexes showed slightly less transfection efficacy compared with unmodified DAB
dendriplex after 3 days of treatment. This might be due to a decrease in proton sponge effect,
occurring as a consequence of the substitution on the dendrimers. As cholesterol has previously
been shown to disrupt endosomal membrane 47, another possibility would be that the dendrimers
should be conjugated to an even higher amount of cholesterol to increase their gene expression
ability. This hypothesis is further reinforced by the fact that all the generation 1-, generation 2and generation 3-PAMAM dendrimers conjugated to cholesterol at 40% mole ratio of
cholesterol/primary amine displayed a significantly higher gene expression than their unmodified
dendriplexes.30-31
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Figure 10. Transfection efficacy of low-cholesterol (A) and high-cholesterol (B) dendriplexes at
various dendrimer: DNA weight ratios in PC3 prostate cancer cells. (Optimal DAB: DNA ratio:
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5:1) (n=5) (A: P <0.05 for all treatments compared with DAB, B: only 10:1 treatment was not
significantly different from DAB treatment)

Cellular uptake of dendriplexes
Qualitative analysis
The cellular uptake of the complex formed between fluorescein-labeled DNA and dendrimerbased vesicles, was qualitatively confirmed in PC-3 cells using confocal microscopy (Figure 11).
Fluorescein-labeled DNA was disseminated in the cytoplasm of the cells after treatment with
both low-and high-cholesterol vesicles, at both 5:1 and 10:1 ratios. The DNA uptake appeared to
be the highest following treatment with high-cholesterol vesicles at a dendrimer: DNA weight
ratio of 10:1. It also appeared to be more pronounced in the cells treated with the vesicle
complexes than with DAB dendriplex. No co-localization of DNA in the nuclei was visible after
2 h incubation.
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Figure 11. Confocal microscopy images of the cellular uptake of fluorescein-labelled DNA (2.5
μg/dish), complexed with low-cholesterol dendrimer (A: dendrimer: DNA ratio 5:1, B:
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dendrimer: DNA ratio 10:1), high-cholesterol dendrimer (C: dendrimer: DNA ratio 5:1, D:
dendrimer: DNA ratio 10:1), DAB dendrimer (E) or free in solution (F), after 2h incubation with
PC3-Luc cells. Blue: nuclei stained with DAPI (excitation: 405 nm laser line, bandwidth: 415–
491 nm), green: fluorescein-labelled DNA (excitation: 453 nm laser line, bandwidth: 550–620
nm) (Magnification: ×40).

Quantitative analysis
Qualitative results were quantitatively confirmed by flow cytometry. Treatment of PC3 cells
with the low-cholesterol complex resulted in the highest cellular fluorescence at a dendrimer:
DNA ratio of 5:1 (3970 ± 184 arbitrary units (a.u.)), which was respectively 12.5-fold and 15.4fold higher than that observed after treatment with DAB dendriplex (315 ± 10.50) and DNA
solution (257 ± 6 a.u.) (Figures 12 and S11). It was also 1.3-fold higher than that when using a
dendrimer: DNA weight ratio of 10:1 instead of 5:1 (3022 ± 55 a.u.).
Increased cellular fluorescence was also observed following treatment with high-cholesterol
complex at a 10:1 ratio (2775 ± 81 a.u.). It was respectively 8.8-fold and 10.78-fold higher than
that observed following treatment with DAB dendriplex and DNA solution, but also 1.9-fold
higher than when using a ratio of 5:1 (1414 ± 63 a.u.). In addition, treatment of the cells with
naked DNA resulted in a weak DNA uptake, demonstrating the failure of DNA to be taken up by
prostate cancer cells without the assistance of a carrier.
This enhanced delivery of DNA to the cancer cells most likely resulted from the highly
positive charges of the dendriplexes, as positive charges increase their electrostatic interactions
with the negatively charged cellular membranes and facilitate cellular uptake.
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However, this

51

did not result in an increased expression of the reporter gene compared with the unmodified
DAB dendriplex.

Figure 12. Quantification of the cellular uptake of fluorescein-labeled DNA (2.5 μg/well),
complexed with low- or high-cholesterol dendrimers (DPSCL and DPSCH respectively), DAB
dendrimer, or free in solution, after 2 h incubation with PC3-Luc cells, using flow cytometry
(n=3) (*: P <0.05 compared with DAB-DNA)

To the best of our knowledge, this is the first report on cholesterol-bearing PEGylated
polypropylenimine dendrimers forming spontaneous, redox-sensitive, cationic stable vesicles
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able to carry hydrophilic or hydrophobic compounds as well as DNA, leading to gene expression
in prostate cancer cells. Other cholesterol-modified dendrimers have previously been reported
(spermine-functionalized dendrons conjugated with cholesterol
PAMAM dendrimers)

30-31, 49

47

, cholesterol-conjugated

, but for use as a non-viral gene delivery system only, and without

redox sensitivity. Amphiphilic dendrimers based on polypropylenimine dendrimers have also
been shown to self-assembly, but without redox-sensitivity or entrapment of any drugs or genes.
50

Redox-responsive PAMAM has previously been reported as delivery systems, but to deliver

either DNA or hydrophobic drug, and this without the formation of vesicles.

51-52

These novel

cholesterol-bearing PEGylated poly(propylene imine) dendrimer-based vesicles therefore hold
promising prospects as redox-sensitive drug and gene delivery systems for cancer therapy.
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CONCLUSION
In this proof of concept study, two disulphide-linked cholesterol-bearing PEGylated dendrimers
have been successfully synthesized through in situ two-step reaction. Both the low and high
cholesterol-bearing dendrimers were able to spontaneously self-assemble into stable vesicles in
PBS (pH 7.4), with lower critical aggregation concentration values for high cholesterol-bearing
vesicles. These cationic, nano-sized vesicles, or dendrimersomes, were able to entrap both
hydrophilic and hydrophobic guests, and also showed a redox-responsive sustained release of the
entrapped guests at higher glutathione concentration corresponding to reducing environment in
the intracellular compartment. In addition, both dendrimeric vesicles were able to condense more
than 85 % of the DNA at all tested ratios for the low-cholesterol vesicles, and at dendrimer:
DNA weight ratios of 1:1 and higher for the high-cholesterol vesicles. These vesicles resulted in
an enhanced cellular uptake of DNA, by up to 15-fold compared with naked DNA with the lowcholesterol vesicles. Consequently, they increased gene transfection on PC3 prostate cancer cell
line, with the highest transfection being obtained with low-cholesterol vesicle complex at a
dendrimer: DNA weight ratio of 5:1 and high-cholesterol vesicle complex at a dendrimer: DNA
weight ratio of 10:1. These transfection levels were about 5-fold higher than that observed when
treated with naked DNA. These novel cholesterol-bearing PEGylated dendrimer-based vesicles
are therefore very promising as redox-sensitive drug and gene delivery systems for future
applications in cancer therapy.
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Figure S1. FTIR spectra of (A) low-cholesterol and (B) high-cholesterol dendrimers
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Figure S2. FTIR spectra of (A) OPSS-PEG-SCM (B) DAB dendrimer and (C) thiocholesterol
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Figure S3. 1H-NMR spectrum of low-cholesterol (A) and high-cholesterol (B) dendrimer (in
CDCl3, 500 MHz ).
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Figure S4. MALDI-TOF MS spectra of low-cholesterol (A) and high-cholesterol dendrimers (B)
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Section S1. Lipid loading Calculations
The amount of lipid or cholesterol (CHOL) loading to modified dendrimer is calculated as the
weight of conjugated CHOLSH as a percentage of the total average molecular weight:
Lipid-loading (%) = {(n x 401.72)/[M]+}x 100
Where, n is the number of cholesterol conjugated to modified dendrimer and [M]+ is the average
molecular weight of the modified dendrimers analyzed from MALDI-TOF MS.
Low-cholesterol dendrimer (DPSCL), lipid loading (%) = {(1 x 401.72)/4210} x 100 = 9.54%
High-cholesterol dendrimer (DPSCH), lipid loading (%) = {(2 x 401.72)/6492} x 100 = 12.37%

Figure S5. 1H-NMR spectrum of high-cholesterol dendrimer (in D2O, 500 MHz)
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Figure S6. Fluorescence spectra of N-Phenyl-1-naphthylamine in presence or absence of lowcholesterol (A) and high-cholesterol (B) dendrimer dispersions at various concentrations in PBS
buffer (pH 7.4)

73

% Transmittance

100

90

80

70
20

40

60

80

100

o

Temperature ( C)

Figure S7. Transmittance of low-cholesterol (■) and high-cholesterol (○) dendrimer-based
vesicles in function of temperature (400 µg/mL, pH 7.4).
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Table S1. Results of phase transition analysis for low-cholesterol (DPSCL) and high-cholesterol
(DPSCH) vesicles by DSC
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Figure S8. Fluorescence emission spectra of Nile Red entrapped in low-cholesterol (A, C, E)
and high-cholesterol (B, D, F) dendrimer-based vesicles (100 µg/mL in PBS, pH 7.4) in presence
of glutathione (10 µM (A, B) and 10 mM (C, D)) at various time intervals (control: no
glutathione) (E, F)
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Figure S9. Gel retardation assay of low-cholesterol DAB (DPSCL) dendriplexes at various
dendrimer: DNA weight ratios (0.5:1, 1:1, 2:1, 5:1, 10:1,20:1)

77

Figure S10. Gel retardation assay of high-cholesterol DAB (DPSCH) dendriplexes at various
dendrimer: DNA weight ratios (0.5:1, 1:1, 2:1, 5:1, 10:1, 20:1)
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Figure S11. Flow cytometry histograms of PC3-Luc cells following 2 hours incubation with
low-cholesterol dendriplex (dendrimer: DNA weight ratio 5:1 (A) or 10:1 (B)), high-cholesterol
dendriplex (dendrimer: DNA weight ratio 5:1 (C) or 10:1 (D)) (Controls: DAB dendriplex (5:1)
(E), DNA solution (F))
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